Ironwood Pharmaceuticals Upgraded by Credit Suisse to Outperform (IRWD)
Ironwood Pharmaceuticals (NASDAQ: IRWD) was upgraded by analysts at Credit Suisse from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Friday, TheFlyOnTheWall.com reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cantor Fitzgerald raised their price target on shares of Ironwood Pharmaceuticals from $7.00 to $12.00 in a research note to investors on Wednesday. They now have a “sell” rating on the stock. Separately, analysts at Bank of America reiterated a “neutral” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Tuesday. They now have a $18.00 price target on the stock, up previously from $15.00. Finally, analysts at Wedbush upgraded shares of Ironwood Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, February 13th. They now have a $13.00 price target on the stock, up previously from $11.00.
Six analysts have rated the stock with a buy rating, six have given a hold rating, and two have issued a sell rating to the company’s stock. Ironwood Pharmaceuticals has a consensus rating of “overweight” and an average price target of $16.27.
Shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) opened at 17.68 on Friday. Ironwood Pharmaceuticals has a 52 week low of $10.01 and a 52 week high of $17.74. The stock’s 50-day moving average is currently $14.51. The company’s market cap is $1.904 billion.
Ironwood Pharmaceuticals (NASDAQ: IRWD) last posted its quarterly earnings results on Tuesday, January 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.08. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $16.17 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was down 16.1% on a year-over-year basis. Analysts expect that Ironwood Pharmaceuticals will post $-2.21 EPS for the current fiscal year.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.